Healthcare
Jazz Pharmaceuticals plc(JAZZ)
Live Price
Offline$224.66
-1.00% today
1Y Change
+109.73%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $12.69B
- Revenue Growth
- +4.9%
- EPS Growth
- -164.5%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Jazz Pharmaceuticals plc (JAZZ) is a Healthcare stock with a market cap of $12.69B and listed on NASDAQ. The stock last traded around $224.66 and up 109.7% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +4.9%, EPS growth of -164.5%, a dividend yield of 0.0%. What stands out right now is revenue +4.9%, EPS -164.5%, free cash flow -3.8% with operating margin 5.3% and ROIC 1.2%. Valuation is more restrained than many high-expectation growth names at price/sales 3.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines JAZZ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.9% vs +7.6% peer median
Operating Margin
Below sector median
+5.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +4.9% and EPS is at -164.5%, with operating margin around 5.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +7.7% | +7.3% | +8.8% |
2026 Feb 24, 2026 | +1.8% | +13.2% | +7.4% | +6.4% |
2025 Nov 5, 2025 | +36.6% | -2.3% | -0.4% | +21.6% |
Benchmark Edge
JAZZ vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
JAZZ
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
JAZZ Max Drawdown
-11.42%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for JAZZ and SPY.
Company Overview
Jazz Pharmaceuticals plc
NASDAQ Global Select
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
- Leadership
- Renee D. Gala
- IPO Date
- Jun 1, 2007
- Employees
- 2.8k
- Street Address
- Waterloo Exchange
- Mailing
- Dublin, 4
- Region
- Dublin, IE
- Reporting Currency
- USD
- Investor Line
- 353 1 634 7800
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 120.1
- Price/Sales
- 3.0
- Price/Book
- 2.9
Growth
- Revenue
- +4.9%
- EPS
- -164.5%
- Free Cash Flow
- -3.8%
Profitability
- Gross Margin
- 88.2%
- Operating Margin
- 5.3%
- Net Margin
- -8.3%
- ROE
- -8.8%
- ROIC
- 1.2%
Balance Sheet
- Debt/Equity
- 1.25
- Current Ratio
- 1.86
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.